[go: up one dir, main page]

WO2010135493A3 - Alzheimer's disease imaging agents - Google Patents

Alzheimer's disease imaging agents Download PDF

Info

Publication number
WO2010135493A3
WO2010135493A3 PCT/US2010/035517 US2010035517W WO2010135493A3 WO 2010135493 A3 WO2010135493 A3 WO 2010135493A3 US 2010035517 W US2010035517 W US 2010035517W WO 2010135493 A3 WO2010135493 A3 WO 2010135493A3
Authority
WO
WIPO (PCT)
Prior art keywords
amyloid
alzheimer
imaging agents
deposits
disease imaging
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2010/035517
Other languages
French (fr)
Other versions
WO2010135493A2 (en
Inventor
Mark M. Goodman
Fanxing Zeng
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Emory University
Original Assignee
Emory University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Emory University filed Critical Emory University
Publication of WO2010135493A2 publication Critical patent/WO2010135493A2/en
Publication of WO2010135493A3 publication Critical patent/WO2010135493A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0453—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
    • C07D277/66—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2 with aromatic rings or ring systems directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Neurology (AREA)
  • Optics & Photonics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

This invention provides compounds and methods of imaging amyloid deposits using radiolabeled compounds. This invention also provides a method of inhibiting the aggregation of amyloid proteins to form amyloid plaques or deposits, a method of determining a therapeutic compound's ability to inhibit aggregation of amyloid protein, and a method of delivering a therapeutic agent to amyloid deposits.
PCT/US2010/035517 2009-05-20 2010-05-20 Alzheimer's disease imaging agents Ceased WO2010135493A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17983609P 2009-05-20 2009-05-20
US61/179,836 2009-05-20

Publications (2)

Publication Number Publication Date
WO2010135493A2 WO2010135493A2 (en) 2010-11-25
WO2010135493A3 true WO2010135493A3 (en) 2011-04-21

Family

ID=43126762

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2010/035517 Ceased WO2010135493A2 (en) 2009-05-20 2010-05-20 Alzheimer's disease imaging agents

Country Status (1)

Country Link
WO (1) WO2010135493A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107501123B (en) * 2017-07-03 2020-04-28 华中科技大学鄂州工业技术研究院 Preparation method and application of permanently charged hydrazine carbohydrate label
CN107400078A (en) * 2017-07-03 2017-11-28 华中科技大学鄂州工业技术研究院 Preparation method and application with permanent charge amber esters sugar label

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090105266A1 (en) * 2007-04-19 2009-04-23 Ralf Glatthar Organic compounds
US20090118275A1 (en) * 2007-09-24 2009-05-07 Genentech, Inc. Thiazolopyrimidine p13k inhibitor compounds and methods of use

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090105266A1 (en) * 2007-04-19 2009-04-23 Ralf Glatthar Organic compounds
US20090118275A1 (en) * 2007-09-24 2009-05-07 Genentech, Inc. Thiazolopyrimidine p13k inhibitor compounds and methods of use

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LEE, Y. R. ET AL.: "Synthesis of thia(oxa)zolopyridines and their inhibitory activities for beta-amyloid fibrillization", BULLETIN OF THE KOREAN CHEMICAL SOCIETY, vol. 29, no. 12, 2008, pages 2331 - 2336, XP008150933, DOI: doi:10.5012/bkcs.2008.29.12.2331 *

Also Published As

Publication number Publication date
WO2010135493A2 (en) 2010-11-25

Similar Documents

Publication Publication Date Title
WO2007033080A3 (en) Alzheimer's disease imaging agents
FR13C0034I1 (en)
MX2007007380A (en) Stilbene derivatives and their use for binding and imaging amyloid plaques.
EP2382176A4 (en) Use of nitrogen-containing curcumin analogs for the treatment alzheimer's disease
WO2008073350A3 (en) Acetylene derivatives and their use for binding and imaging amyloid plaques
WO2008003943A3 (en) Inhibition of alpha-synuclein aggregation
WO2011045415A3 (en) Imaging agents and their use for the diagnostic in vivo of neurodegenerative diseases, notably alzheimer's disease and derivative diseases
IL188165A0 (en) Method for the diagnosis of alzheimer's disease
IL208350A0 (en) Aminodihydrothiazine derivatives as bace inhibitors for the treatment of alzheimer's disease
IL194789A0 (en) Terphenyl derivatives for treatment of alzheimer's disease
WO2011072257A3 (en) Amyloid binding agents
EP2306824A4 (en) Iontophoretic delivery of curcumin and curcumin analogs for the treatment of alzheimer's disease
WO2007092861A3 (en) Inhibitors specific of presenilin-1 and their uses
WO2006078384A3 (en) Stilbene derivatives and their use
MA35347B1 (en) Therapeutic methods
IL185410A0 (en) Use of 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione in the treatment of parkinson's disease
WO2007016352A3 (en) Oral liquid losartan compositions
WO2008026040A3 (en) 68ga-labeled peptide-based radiopharmaceuticals
WO2010135493A3 (en) Alzheimer's disease imaging agents
WO2008050133A3 (en) Inhibition of beta-amyloid aggregation
WO2008057599A3 (en) Methods for the treatment of abeta related disorders and compositions therefor
WO2006136454A3 (en) Use of inhibitors of n-methyl transferases for the therapy of parkinson's disease
IL220163A0 (en) Methods for the preparation of indazole-3-carboxyclic acid and n-(s)-1- azabicyclo[2.2.2] oct-3-yl-1h-indazole-3-carboxamide hydrochloride salt
UA91996C2 (en) Stilbene derivatives and their use for binding and imaging amyloid plaques
EP2099476A4 (en) Methods of treating alzheimer's disease

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10778364

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10778364

Country of ref document: EP

Kind code of ref document: A2